--BioAge Labs, Inc., a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the launch of ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

BioAge Labs is collaborating with Age Labs AS to comprehensively profile over 17,000 samples from the HUNT Biobank, enhancing their drug discovery capabilities focused on aging-related diseases.

News provided by BioAge Labs, Inc. Jun 17, 2025, 9:00 AM ET Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norwayto accelerate discovery of ...

BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity ...

BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring body composition and muscle function, ...

The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

That drug, called retatrudide, is currently in clinical trials that indicate even greater achievable weight loss (up to 24%) compared to the original GLP-1 drugs (6-15%).